Avia Logo

Products /

Intrommune Therapeutics

Intrommune Therapeutics

Intrommune Therapeutics

Overview


Select which hospital or health system you work at and see a personalized compatibility level.

Avia Summary

o
Intrommune Therapeutics is a solution provided by Intrommune Therapeutics. It belongs to the digital health solution Digital Therapeutics (DTx).
o
Some other resource(s) that may be helpful in learning about Intrommune Therapeutics include: Exploring the Potential of Digital Therapeutics (WEBINAR) and A Buyer’s Guide to Digital Therapeutics
DESCRIPTION
Intrommune Therapeutics is a clinical stage biotechnology company that is developing convenient, safe and effective options for individuals suffering with food allergies. Intrommune’s therapies are delivered through a platform that integrates simply into a person’s daily routine to enable them and their loved ones to live their lives without fear. The Company’s Oral Mucosal Immunotherapy (OMIT) platform is based on the well-accepted principles of immunotherapy. OMIT utilizes a specially formulated toothpaste that optimizes exposure of allergenic proteins to a patient’s immune system, while cleaning their teeth. The initial product in development is INT301 for the treatment of peanut allergy. The lack of treatments makes food allergies an area of tremendous unmet need. The FDA has only approved one product for any food allergy, a peanut allergy immunotherapy that requires you to ingest peanut protein. As desperate as patients are for solutions, due to significant adverse events and difficulty in administration, only 1 in 10 eligible patients are willing to ingest peanut protein. Nonetheless, the company was recently acquired for $2.6 billion. With minimal options, patients and caregivers must resort to attempting to avoid allergy-triggering foods in the often-futile hope of preventing severe allergic reactions. In short, patients, parents, providers and payors are all seeking a safe, efficacious, and easy to administer product such as INT301. Intrommune Therapeutics’ Phase 1b study in individuals with peanut allergy is on-going and is on a development timeline with significant near-term value inflection events expected over the next 12 months
Read more
CLIENT TYPES
None provided
EHR integration

None provided
None provided
None provided
None provided
Use cases and differentiators

None provided
None provided
None provided
None provided
Company information

Media


Images

No images provided

Videos

No videos provided

Downloads

No content provided

Reviews


Filter reviews


Overall Score

0 review


Sort by:
Most Recent
Sort by:
Most Recent
Oldest
Most Helpful

Filter reviews


Reviewer’s Rating
5
4
3
2
1

Reviewer’s Role
  • End user
  • Project manager
  • IT / Technical support
  • Executive sponsor
  • Internal consultant
  • Other

Reviewer’s Org Size
  • XL ($5B+ NPR)
  • L ($3-5B NPR)
  • M ($1-3B NPR)
  • S ($0.2-1B NPR)
  • XS (< $0.2B NPR)

Reviewer’s Org EMR compatibility

Reviewer’s Org Type
  • AMC
  • Pediatric Facilities
  • ACO
  • Rural Presence

Looking for reviews on Intrommune Therapeutics?

Submit your work email and we'll notify you when new reviews have been added.

Clients


Filter clients


Type
  • Partner

  • Vendor

  • Health System

  • Other

Explore Related Resources
back to top